Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COCA study of esomeprazole and Coca-Cola effects on capecitabine absorption
NL-OMON46595Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine and esomeprazole in colorectal cancer (CRC) and Nonhematologic neoplasms (2 arms), sponsored by Erasmus MC. Primary endpoint: Capecitabine AUC comparison. Started Feb 2018; status: active, not recruiting.
02
Drugs
capecitabineesomeprazole
03
Conditions
colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46595.